

I hereby certify that this correspondence is being deposited with the United States Postal Services as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on *March 18, 1996*.



LUD 5354.3 BELINDH

#4 1/2

WAB
1/28/97

By *Howard J. Pfeiffer*
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Yao-Tseng Chen, et al.
Serial No. : 08/560,024
Filed : November 17, 1995
For : MONOCLONAL ANTIBODIES WHICH BIND TO TUMOR REJECTION ANTIGEN PRE-CURSOR MAGE-1, RECOMBINANT MAGE-1, AND MAGE-1 DERIVED IMMUNOGENIC PEPTIDES

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with their duty of disclosure, applicants wish to make the attached references of record.


Boon, et al., PCT/US92/04354 is cited in the specification (e.g., page 7, line 21, et seq.). This reference, which corresponds to the parent of the subject application, teaches various MAGE genes, including MAGE-1. A peptide is taught, i.e., MZ2-E (SEQ ID NO: 26); however, this peptide was not used to provoke antibody production. It is taught to stimulate CTLs. It is well known in the art that T cell stimulating peptides do not stimulate antibodies as well.

* * *

The attached is, to the best of applicants' knowledge, the art most relevant to the subject matter claimed in this case, as there is no suggestion in the art, let alone a teaching, that MAGE proteins or peptides derived therefrom could be used to generate monoclonal antibodies.

Respectfully submitted,

FELFE & LYNCH

By 
Norman D. Hanson
Reg. No. 30,946

805 Third Avenue
New York, N.Y. 10022
(212) 688-9200